Basal epithelial stem cells cross an alarmin checkpoint for postviral lung disease

Kangyun Wu, … , Samantha A. Morris, Michael J. Holtzman

*J Clin Invest.* 2021;131(19):e149336. [https://doi.org/10.1172/JCI149336](https://doi.org/10.1172/JCI149336).

**Graphical abstract**

Find the latest version:

[https://jci.me/149336/pdf](https://jci.me/149336/pdf)
Basal epithelial stem cells cross an alarmin checkpoint for postviral lung disease

Kangyun Wu,1 Kenji Kamimoto,2,3 Yong Zhang,1 Kuangying Yang,1,4 Shamus P. Keeler,1 Benjamin J. Gerovac,1 Eugene V. Agapov,1 Stephen P. Austin,1 Jennifer Yantis,1 Kelly A. Gissy,1 Derek E. Byers,1 Jennifer Alexander-Brett,1,5 Christy M. Hoffmann,1 Matthew Wallace,1 Michael E. Hughes,1,2 Erika C. Crouch,5 Samantha A. Morris,2,3 and Michael J. Holtzman1,6

Introduction

Epithelial barrier sites such as skin, gut, and lungs are charged with host protection that relies on endoderm-derived epithelial stem cells to repair any possible damage (1–3). When the injury is due to infection, this barrier is further responsible for a process that contains and helps eliminate the pathogen (4, 5). For this task, barrier epithelial cells must also communicate upstream and downstream with immune cells to coordinate the host response (6–8).

However, in some cases, barrier activities might be reprogrammed toward a detrimental response that can result in disease. Indeed, a relatively stereotyped pattern of epithelial injury and acute illness that progresses to epithelial remodeling and chronic disease is well established after severe infection with respiratory viruses (9), including epidemic influenza viruses (10). In fact, morbidity and mortality due to respiratory viral infections often peak after infection in experimental models (mainly using influenza virus). Single-cell and lineage-tracing technologies identified a distinct subset of basal epithelial stem cells (basal ESCs) that extend into gas-exchange tissue to form long-term bronchiolar-alveolar remodeling regions. Moreover, this cell subset was selectively expanded by crossing a cell-growth and survival checkpoint linked to the nuclear-localized alarmin IL-33 that was independent of IL-33 receptor signaling and instead connected to autocrine chromatin accessibility. This mechanism creates an activated stem-progenitor cell lineage with potential for physiological or pathological function. Thus, conditional loss of Il33 gene function in basal epithelial cells disrupted the homeostasis of the epithelial barrier at skin and gut sites but also markedly attenuated postviral disease in the lung based on the downregulation of remodeling and inflammation. Thus, we define a basal ESC strategy to deploy innate immune machinery that appears to overshoot the primordial goal of self-defense.

Our findings reveal new targets to stratify and correct chronic and often deadly postviral disease.
Viral infection reprograms basal ESCs for continued expansion. As introduced above, we engaged a mouse model in which the peak of remodeling disease occurs 49 days after SeV infection and is well characterized at that time point using microarray-based gene expression profiling (28). Here, we took advantage of an updated RNA-Seq approach for unbiased whole-genome lung expression on day 12 after SeV infection, which might represent an earlier switch point from acute infectious illness to chronic remodeling disease, and on day 21, when the full features of the remodeling disease become detectable. The new analysis revealed prominent induction of basal-epithelial cell markers 12 days after infection, including a heretofore unrecognized increase in Aqp3 mRNA along with conventional basal cell markers typified by Krt5, Trp63, and Ngfr mRNA (Figure 1 and Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/JCI149336DS1). Moreover, increases in basal cell marker levels at day 12 continued to progress to maximal levels 21–49 days after infection, based on RNA-Seq and the corresponding quantitative PCR (qPCR) assay, and were correlated with subsequent mucinous differentiation marked by Muc5ac gene expression (Figure 2, A and B). This pattern of gene expression developed in concert with bronchiolar-alveolar sites of mucinous differentiation based on periodic acid–Schiff–hematoxylin (PAS-hematoxylin) staining 49 days after infection (Figure 2C), consistent with mucous cell formation as reported previously (5). This detrimental outcome is likely reprogrammed from the intended purpose of wound healing and host defense (31). However, it remained uncertain whether similar or distinct activation of epithelial stem cells might be (a) found after viral infection; (b) linked to tissue remodeling and/or immune cell activation as a basis for PVLD; or (c) controlled as a means to prevent this type of disease.

Here, we address this issue in studies of a mouse model of PVLD caused by the natural rodent pathogen Sendai virus (SeV). We chose this model for several reasons: (a) the pattern of acute illness progresses from proximal to distal airspaces for a bronchiolar-alveolar (centrilobular) pattern that is characteristic of natural infection (5, 32); (b) acute infectious illness is linked to progressive and long-term lung remodeling disease in a genetically susceptible but also widely engineered inbred strain (C57BL/6) (33–35); (c) these experimental conditions allow application of highly informative single-cell, lineage-tracing, gene reporter, and conditional gene-knockout technologies; and (d) the disease components detected to date are also routinely found in other experimental models of inflammatory lung disease and in humans with respiratory disease linked to viral infection (5, 8, 10, 28–30, 36). In the present study, the combination of these advanced approaches revealed a subset of basal epithelial stem cells (basal ESCs) that are critical for homeostasis at barrier sites in skin and gut but are also reprogrammed for the excessive growth, migration, and immune activation that drive postviral disease in the lungs. Both physiological and pathological phenotypes depend on intracellular IL-33 function as a nuclear alarmin and can be segregated from secreted IL-33 actions for a feedforward type 2 immune response that promotes basal ESC differentiation into mucous cells. This pathway also combines with basal ESC–derived immune signaling for tissue macrophage recruitment, activation, and consequent inflammation. Our identification of an intersection between basal ESCs and innate immunity thus provides an unexpected addition to the conventional paradigm for the actions of the epithelial barrier. The latest circuitry for basal ESC function also defines unexpected components that can be applied to the unmet need for a precise, disease-modifying strategy relevant to the critical problem of PVLD.

**Results**

Viral infection reprograms basal ESCs for continued expansion. As introduced above, we engaged a mouse model in which the peak of remodeling disease occurs 49 days after SeV infection and is well characterized at that time point using microarray-based gene expression profiling (28). Here, we took advantage of an updated RNA-Seq approach for unbiased whole-genome lung expression on day 12 after SeV infection, which might represent an earlier switch point from acute infectious illness to chronic remodeling disease, and on day 21, when the full features of the remodeling disease become detectable. The new analysis revealed prominent induction of basal-epithelial cell markers 12 days after infection, including a heretofore unrecognized increase in Aqp3 mRNA along with conventional basal cell markers typified by Krt5, Trp63, and Ngfr mRNA (Figure 1 and Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/JCI149336DS1). Moreover, increases in basal cell marker levels at day 12 continued to progress to maximal levels 21–49 days after infection, based on RNA-Seq and the corresponding quantitative PCR (qPCR) assay, and were correlated with subsequent mucinous differentiation marked by Muc5ac gene expression (Figure 2, A and B). This pattern of gene expression developed in concert with bronchiolar-alveolar sites of mucinous differentiation based on periodic acid–Schiff–hematoxylin (PAS-hematoxylin) staining 49 days after infection (Figure 2C), consistent with mucous cell formation as reported previously (5). In concert with gene expression data, these remodeling sites also contained Aqp3*Krt5* basal cells (Figure 3A). In bronchiolar-alveolar locations, these...
Aqp3+ basal cells (Figure 4F). We observed smaller fold increases in cell proliferation marked by Ki-67 tracked primarily to a subset of sites excluded Sftpc+ AT2 cells but still maintained podoplanin+ (Pdpn+) cells (Figure 3C). This combination was reflected by Aqp3+Pdpn+ costaining in cells with basal cell morphology adjacent to Aqp3+Pdpn+ cells with AT1 cell morphology (Figure 3C). Together, the results indicated that basal cell expansion starts in bronchiolar sites and extends further distally to alveolar sites, as suggested for the response to influenza A virus (IAV) infection (25, 26). In parallel with this process, we also found increases in Sftpc+ AT2 cells in alveolar regions (Figure 3D). Bronchiolar-alveolar remodeling was detectable on day 12 (Figure 3E) and alveolar remodeling as soon as 5 days after infection (Figure 3F), both of which were reflected by the quantitation of cell markers (Figure 3G) and are suggestive of distinct remodeling mechanisms for airway and alveolar compartments.

Relevant to this observation, analysis of lung RNA-Seq data also showed marked increases in genes connected to cell-cycle activation and progression, particularly 12 days but also 21 days after SeV infection (Figure 1). Consistent with these findings, we observed increases in lung levels of Ki67 mRNA (Figure 4A) and Ki-67 immunostaining that also peaked at 12–14 days but continued out to 49 days after infection (Figure 4, B and C, and Supplemental Figure 2A). Tissue costaining revealed further localization of Ki-67 expression primarily to basal and AT2 cells (Figure 4, D and E), in agreement with the above-noted increases in these 2 cell populations (Figure 3G), and confirming the delay from cell-cycle activation to the change in cell numbers. Flow cytometric analysis of lung epithelial cells (CD45−CD31−EpCAM+) demonstrated that cell proliferation marked by Ki-67 tracked primarily to a subset of Aqp3+ basal cells (Figure 4F). We observed smaller fold increases in Aqp3+ cells, consistent with a lower-fold expansion of AT2 cells, since this flow cytometry gate (EpCAM−Aqp3+) contained Sftpc mRNA as a validated AT2 cell marker and Il33 mRNA as a possible marker for this population in mice (Supplemental Figure 2B).

Consistent with the preceding results for cell proliferation, EpCAM−Aqp3− cells generated lung spheroids that maintained an Aqp3+ basal cell phenotype in 3D organoid cultures (Figure 4G) and differentiated into Muc5ac+ mucous cells in response to IL-13 under these conditions (Supplemental Figure 2, C–E). Moreover, EpCAM−Aqp3− cells formed lung spheroids at higher efficiency compared with EpCAM−Aqp3+ cells (Figure 4H). Additional flow cytometry showed that Aqp3− cells represented a proliferative subset of Itga6+ cells (Figure 4I and Supplemental Figure 2, F and G), consistent with evidence of Itga6+ basal progenitor cells in mouse lung (19) and comparable cells in humans (28). Indeed, flow cytometry also showed corresponding increases in Aqp3+ cells (Figure 4J), in step with cell numbers found in the lungs in situ (Figure 4K), again as a subset of Itga6+ cells (Supplemental Figure 2H). Together, the results identified an Aqp3+ basal ESC subset that was activated for growth in concert with AT2 cell hyperplasia as key long-term remodeling components in PVLD.

Single-cell analysis defines ESC subsets for post-viral growth and differentiation. To better define virus-sensitive epithelial cell populations, we next annotated gene expression in relation to lung epithelial cell expansion using single-cell RNA-Seq (scRNA-Seq). Gene expression patterns of lung epithelial cells (CD45−CD31−EpCAM+) across 3 sample conditions (PBS control challenge and 12 or 21 days after SeV infection) revealed 13 clusters of epithelial cells based on nearest-neighbor, heatmap, and dot plot analyses, with basal cells identified as 3 distinct cell clusters (designated clusters 1–3; Figure 5A and Supplemental Figure 3, A and B). Gene expression for each sample condition mapped onto cell-type clusters and specific cell counts for each cell population showed that basal cell cluster 3 appeared transiently on day 12, whereas basal cell clusters 1 and 2 were more prominent later, 21 days after SeV infection (Figure 5, A and B). Cell-cycle gene expression mapped onto cell-type clusters also showed a transient appearance of basal cell cluster 3 twelve days after SeV infection that coincided with the appearance of AT2 cell cluster 9 (Figure 5C). To relate basal cell proliferation and survival to ontogeny, we also used scRNA-Seq data to infer cell trajectory. For this approach, we applied partition-based graph abstraction (PAGA) (37) for a pseudotemporal ordering algorithm followed by RNA velocity analysis of single cells, based on spliced versus unspliced mRNA abundance (38). The combined analysis revealed a parental cluster 1 found at baseline that could give rise to cluster 3 and in turn clusters 1 and 2 to fully account for basal cell expansion (Figure 5D), consistent with the time course for the appearance of basal cell clusters (Figure 5, B and E) and basal cells (Figure 3G).

To further delineate a possible basal cell program for PVLD, we mapped basal cell expansion and differentiation using cell lineage tracing guided by Krt5 as a marker of basal cell clusters (Sup-
were also Krt5 + when isolated from WT mice 21 days after SeV infection. Scale bar: 1 mm. (B) Immunostaining for Aqp3 and Pdpn in lung sections 0–49 days after SeV infection. Scale bar: 1 mm. (C) Immunostaining of bronchiolar-alveolar remodeling sections under the conditions in B. Scale bar: 400 μm. Original magnification, ×3.5 (inset). (D) Immunostaining for Sftpc and Pdpn in lung sections 0–49 days after SeV. Scale bar: 200 μm. (E) Immunostaining for Aqp3 in lung bronchiolar-alveolar sections 49 days after SeV infection. Scale bar: 400 μm. (F) Immunostaining for Sftpc 0–49 days after SeV infection. Scale bar: 200 μm. (G) Quantitation of immunostaining for Aqp3, Krt5, Sftpc, and Pdpn in lung sections 0–49 days after SeV infection. Data represent results from a single experiment with 5 mice per condition and were replicated twice.

Figure 3. Progressive long-term lung remodeling after SeV infection. (A) Immunostaining for Aqp3, Krt5, Sftpc, and Pdpn with DAPI counterstaining in lung sections 49 days after SeV or SeV-UV infection. Scale bar: 1 mm. (B) Immunostaining for Aqp3 and Pdpn in lung sections 0–49 days after SeV infection. Scale bar: 1 mm. (C) Immunostaining of bronchiolar-alveolar remodeling sections under the conditions in B. Scale bar: 400 μm. Original magnification, ×3.5 (inset). (D) Immunostaining for Sftpc and Pdpn in lung alveolar sections 0–49 days after SeV. Scale bar: 200 μm. (E) Immunostaining for Aqp3 in lung bronchiolar-alveolar sections 49 days after SeV infection. Scale bar: 400 μm. (F) Immunostaining for Sftpc 0–49 days after SeV infection. Scale bar: 200 μm. (G) Quantitation of immunostaining for Aqp3, Krt5, Sftpc, and Pdpn in lung sections 0–49 days after SeV infection. Data represent results from a single experiment with 5 mice per condition and were replicated twice.

Supplementary Figure 3B and Figure 5E). To validate this approach, we first showed that Aqp3 + basal cells could be efficiently (89%) marked by Krt5 gene expression, since FACS-purified Aqp3 + cells were also Krt5 + when isolated from WT mice 21 days after SeV infection (Supplemental Figure 4, A and B). We therefore tracked the fate of Krt5-GFP-labeled cells in post-SeV disease using lineage tracing with Krt5-Cre-Ert2 ROSA26 mTmG reporter mice that were marked with transient tamoxifen treatment 3 weeks before infection (Supplemental Figure 4C). We found marked Krt5-GFP + trace into airway cells, e.g., Krt5 + and Aqp3 + basal cells, Muc5ac + mucous cells, β-tubulin IV + ciliated cells, and Scgb1a1 + club cells, but not into Sftp + AT2 cells 49 days after SeV infection (Supplemental Figure 4D). We detected no GFP signal after tamoxifen induction without infection or with SeV infection without tamoxifen, providing for specificity of the tracing signal (Supplemental Figure 4D). Colocalization of GFP with Aqp3 and Muc5ac immunostaining was confirmed with confocal microscopy (Supplemental Figure 4E) and quantified by image analysis (Supplemental Figure 4F). Lineage trace into Krt5 + basal cells was similar to the response to IAV infection (25, 26), however, a Krt5 trace into alveolar cells (as high as 72% of AT2 cells; ref. 25) after IAV was not found after SeV infection, consistent with the preservation of proximal-distal ontogeny found in lung development. Our detection of rare basal cells at baseline (Figure 5B) and of a parental cluster 1 (Figure 5D) was consistent with the consequent lineage tracing of Krt5 + expressing cells with disease and the proposal for a stem cell population poised for repair even in the adult lung.

ESC subset growth depends on an unexpected IL-33 checkpoint.

To address the role of basal cell expansion in PVLD, we considered that basal ESCs in humans are a source of IL-33 and, in turn, that IL-33 is required for the type 2 inflammation and mucinous differentiation that is characteristic of chronic lung disease (28). However, previous work indicated that AT2 cells, and not basal cells, might be the predominant epithelial source of IL-33 expression after the development of PVLD in mice, based on in situ hybridization and immunostaining (28, 35). Here, we reassessed this question more comprehensively using mice carrying an Il33 +/+ reporter cassette inserted into the endogenous Il33 gene (8), recognizing that heterozygous Il33 +/+ mice still manifest all aspects of PVLD, including basal cell hyperplasia detected by flow cytometry for EpCAM Aqp3 + cells (Supplemental Figure 5, A and B) and tissue immunostaining for Aqp3 in lung tissue (Supplemental Figure 5C) 21 days after SeV infection. In turn, these mice also progressed to lung remodeling disease, as revealed by qPCR assays for basal cell markers (Aqp3, Krt5, and Trp63), a type 2 immune response (Il33, Il13, Arg1, and Trem2), and mucinous differentiation (Muc5ac) (Supplemental Figure 5, D–G) together with increased mucous cell numbers, as detected by Muc5ac + immunostaining (Supplemental Figure 5H) 49 days after SeV infection. Relevant to the cell source for IL-33 expression, lung immunostaining showed that the IL-33–cherry reporter localized to Sftp + AT2 cells but not to Aqp3 + or Krt5 + basal cells or Scgb1a1 + club cells in Il33 +/+ mice 21 days after SeV infection (Supplemental Figure 5I). Similarly, Il33 +/+ mice crossed with Sftp–GFP reporter mice showed localization of IL-33 signal in Sftp–GFP + AT2 cells but not in Aqp3 + basal cells at baseline and with PVLD, as determined by flow cytometry (Supplemental Figure 5J). These findings were consistent with AT2 cells being a primary source for secreted IL-33 and, in turn, for the stimulation of ST2-bearing immune cells responsible for IL-13 production and the development of type 2 inflammatory disease. Moreover, the time course for these downstream events fit with the detection of Il33 and Il13 mRNA expression in lung tissue and IL-33 and IL-13 protein production in lung tissue and bronchoalveolar lavage fluid after SeV infection (Supplemental Figure 5, K and L).

This conventional analysis confirmed that IL-33 expression was localized in AT2 cells at baseline and during PVLD but did not yet assess earlier events during the peak of cell proliferation or provide a more global and unbiased assessment of all lung epithelial cell populations. We therefore used single-cell analysis with r-distributed stochastic neighbor embedding (r-SNE) feature plots for a more comprehensive profile of IL-33 expression. With this approach, we again found that Il33 gene expression was predominantly localized to AT2 cells (clusters 5–9) at baseline and during PVLD (Figure 6, A and B). However, the sensitivity of this approach also revealed Il33 expression in the subset of cell-cycling basal cells (cluster 3) that appeared in concert with cycling AT2 cells (cluster 9) twelve days after SeV infection (Figure 6, A and B). To further validate Il33 gene expression in basal epithelial cells, we also tracked expression using IL-33–cherry reporter mice. This approach identified an IL-33–cherry + subset of Aqp3 + basal epithelial cells based on flow cytometric analysis (Figure 6C) and immunostaining of FACS-purified cells (Figure 6D) from Il33 +/+ but not WT control mice. Further, we found a comparable IL-33 + subset of Krt5 + cells in lung tissue at bronchiolar-alveolar remodeling sites following immunostaining for the IL-33–cherry reporter (Figure 6E) and for IL-33 itself (Figure 6F). In each case, IL-33 was localized to nuclei in basal cells and was primarily detected 12 days after SeV infection, corresponding to the cell proliferation peak observed with conventional (Figure 4, A–E) and single-cell (Figure 6, A–E) approaches. The restriction of IL-33 nuclear signal to Aqp3 + basal cells, which was maximal 12 days after infection, was consistent with localization of this signal to the Il33 + cycling basal cell cluster 3 on scRNA-Seq. This finding also raised the possibility that IL-33 might be linked to the cell cycle in addition to its conventional role in immune signaling.

To investigate this question, we recognized that the assignment of IL-33 production primarily to AT2 cells in mice is distinct from humans, where IL-33 expression is not detected in AT2 cells (28). However, this difference also provided an opportunity to seg-
regulate potential differences in IL-33 function on the basis of cell type — in this case, basal cells versus AT2 cells. We therefore next assessed Il33 gene function across lung epithelial cell populations using scRNA-Seq in homozygous Il33−/− mice compared with WT controls for each sample condition (PBS and 12 or 21 days after SeV infection). This analysis matrix showed a marked attenuation of basal cell expansion in Il33−/− mice compared with WT mice based on a cluster analysis of combined sample conditions (Figure 7A), number of cells per cluster in each condition (Figure 7B), and Krt5+ cell counts per cluster in each condition (Figure 7C) and across all sample conditions (Figure 7D). The effect of IL-33 deficiency spared cycling basal cells in cluster 3 (and cycling AT2 cells in cluster 9) and was instead confined to basal lineage cells in clusters 1 and 2. These findings suggested an IL-33 require-

Figure 4. Basal ESC growth after SeV infection. (A) Levels of Ki67 mRNA in lung tissue from WT mice 0–49 days after SeV infection. (B) Immunostaining for Ki-67 in lung sections 12 days after SeV infection. Scale bar: 400 μm. (C) Quantitation of Ki67− cells in lung sections 0–49 days after SeV infection. (D) Immunostaining for Ki-67 and Aqp3 in bronchiolar-alveolar sections 12 days after SeV or SeV-UV infection. Scale bar: 200 μm. Original magnification, x3.0 (inset). (E) Immunostaining for Ki-67 and Sftpc in alveolar sections 12 days after SeV or SeV-UV infection. Scale bar: 200 μm. Original magnification, x3.2 (inset). (F) Flow cytograms for Ki-67 in lung epithelial (CD31−CD45−EpCAM+) cells (Aqp3− and Aqp3+ subsets) in WT mice 12 days after SeV or SeV-UV infection. FL2, BluFL2, empty channel. (G) Immunostaining for Aqp3 in a lung spheroid from EpCAM−Aqp3− cells obtained 21 days after SeV infection and placed into 3D organoid culture. Scale bar: 50 μm. (H) Number of lung spheroids from the indicated cell populations, obtained 12–49 days after SeV infection. (I) Number of lung spheroids from the indicated cell populations, obtained 21 days after SeV infection. (J) Flow cytograms of lung epithelial cells (CD31−CD45−EpCAM−restricted and analyzed for EpCAM and Aqp3) after SeV infection or PBS treatment. Values indicate the percentage of cells within each gate. (K) Numbers of the indicated cell populations using the conditions in J. Data represent results from a single experiment with 3–5 mice per condition, and experiments were replicated twice.
ment for late cell-cycle progression and subsequent cell survival in downstream basal lineage cells. In support of this possibility, we found decreased expression of cell-cycle genes (e.g., Cdk1 and Pclaf1) and increased expression of apoptosis genes (e.g., Dapl1 and Psca) in basal cells in Il33–/– mice in cycling clusters relative to WT mice (Supplemental Figure 6A). Further, this pattern of gene regulation was not found in other epithelial cell clusters, including cycling AT2 cells, where cell-cycle activation, but not cell-survival, genes were inducible and dependent on IL-33 function (Supplemental Figure 6, B and C).

Given the capacity for respiratory viral infection to regulate gene expression at the posttranscriptional level (39), we validated our findings for the corresponding control of cell growth and survival at the protein level. Here, we found that effects at the mRNA level were accurately reflected by corresponding decreases in active (phosphorylated nuclear) Cdk1 and Ki-67 (marking cell-cycle activation and cell proliferation) and increases in activated caspase-3 (marking apoptosis) in lung tissue from Il33–/– mice compared with lung tissue from WT mice (Figure 8, A and B). In contrast, the Il33 requirement for basal ESC growth found in Il33–/– mice was not detected in mice deficient for the IL-33 receptor gene (Il1rl1–/–; Figure 8, A and B). Taken together, the findings suggested an unexpected role for intracellular versus extracellular signaling function for IL-33 in the control of the basal cell cycle after viral infection.

To further determine Il33 gene function, we also performed a single-cell assay for transposase-accessible chromatin (ATAC) using sequencing (scATAC-Seq) and thereby defined chromatin accessibility and gene promoter activation in relation to epithelial cell clusters in WT versus Il33–/– mice. We performed this analysis 12 days after SeV infection to capture the peak of Il33 gene activation and proliferation in basal ESCs. Under these conditions, the analysis allowed for cell cluster assignments for scATAC-Seq (Supplemental Figure 7A) that correlated with scRNA-Seq based on cluster-specific markers (Supplemental Figure 7B). Further analysis using the Integrative Genomics Viewer (IGV) showed Krt5 (and neighboring Krt6a) gene promoter activation (adjacent to the transcription start site) in cycling basal cells (cluster 20) from WT mice (Supplemental Figure 7C). Moreover, this signal was downregulated in the corresponding basal cell cluster from Il33–/– mice and was not found in AT2 cell clusters such as cluster 19 (Supplemental Figure 7C). In contrast, Il33 gene promoter activation was detectable in both basal cell and AT2 cell populations in WT mice but was downregulated only in basal cells (cluster 20) in Il33–/– mice (Supplemental Figure 7C). This finding suggested that Il33 gene promoter activity might be sensitive to intracellular IL-33 as we observed for cell-cycle and survival gene expression in basal cells but not AT2 cells. This result is also consistent with differences observed in Il33 gene expression patterns between basal cells and AT2 cells. In addition, analysis revealed an enhancer region in cluster 20 that was also sensitive to Il33 deficiency (Supplemental Figure 7C) and was best matched to a STAT3 transcription factor binding site in embryonic stem cells (40). Together, scRNA-Seq and scATAC-Seq suggested that Il33 gene expression and function are distinct for cycling basal cells and might be linked to STAT3 activation. This scheme is consistent with the EGFR/STAT3 signal transduction for cell growth and mucinous differentiation found in the SeV mouse model and human airway epithelial cells in culture (41).
Specialized IL-33 control of basal ESC subset expansion tracks with PVLD. To further define control of basal ESC expansion in relation to disease phenotype, we compared these 2 endpoints in Il33−/− and Il1rl1−/− mice. As with single-cell analysis, we detected a marked attenuation of Aqp3+ basal cell proliferation 12 days after SeV infection in Il33−/− mice using flow cytometry to determine Ki-67 levels (Figure 9A and Supplemental Figure 8A). We found that basal cell expansion was also attenuated 12 and 21 days after infection, again by flow cytometry for Aqp3 (Figure 9B and Supplemental Figure 8B). We observed the same pattern for stem cell function marked with lung spheroid formation in 3D organoid culture (Figure 9C). In contrast, these endpoints were not significantly affected in Il1rl1−/− mice (Figure 9, A–C). Consistent with these findings, basal ESC formation of spheroids was unaffected by ST2 stimulation with IL-33 in 3D organoid cell culture (Supplemental Figure 8C), and Il1rl1 mRNA and ST2 expression was undetectable in Il1rl1−/− mice (Figure 9, A–C).
able on epithelial cells 0–49 days after SeV infection in vivo (Supplemental Figure 8, D and E). Together, these findings provided additional in vivo and ex vivo evidence for intracellular, but not extracellular, IL-33 function as a requirement for epithelial stem cell expansion. The predominant effect on Aqp3+ cells further indicated a specific IL-33 control over the subset of basal ESCs.

We also observed intracellular IL-33 control over basal ESC expansion in situ. In this case, Aqp3 immunostaining of lung sections showed marked attenuation in Il33−/− mice compared with WT or Il1rl1−/− mice with preservation of IL-33–cherry+ AT2 cells 21 days after SeV infection (Figure 9D). Moreover, lung sections showed marked attenuation of Krt5+ basal cells in Il33−/− mice but not in Il1rl1−/− mice 49 days after SeV infection (Figure 9, E and F). In contrast, we found that Sftpc+ AT2 cell expansion in WT mice was unaffected in Il33−/− and Il1rl1−/− mice (Figure 9F and Supplemental Figure 8F). In concert with the lower basal ESC levels, Il33−/− mice manifested lower induction of lung mRNA markers for basal cells (Supplemental Figure 9A), knockout of Il33 expression (Supplemental Figure 9B), and downregulation of markers for the type 2 immune response (Supplemental Figure 9C) and mucus production (Supplemental Figure 9D). Meanwhile, the levels of mRNA markers for basal cells (Supplemental Figure 9E) and Il33-expressing AT2 cells (Supplemental Figure 9F) were unaffected in Il1rl1−/− mice, despite a disruption of type 2 immune activation (Supplemental Figure 9G) and mucus production (Supplemental Figure 9H). Along with changes at the mRNA level, we noted a marked attenuation of lung histopathology in Il33−/− mice based on PAS staining for mucus production and hematoxylin staining for cellularity (Supplemental Figure 9I). We confirmed these observations with a corresponding quantitative morphologic analysis (Supplemental Figure 9J). We observed similar, albeit slightly less, attenuation of histopathology based on PAS+ and hematoxylin+ staining in Il1rl1−/− mice (Supplemental Figure 9, I and J), indicating the relative insensitivity of this approach for specific monitoring of basal ESC expansion and its possible functional role in PVLD. Indeed, we readily detected a correction of Aqp3+ basal cell expansion and bronchiolar-alveolar remodeling in Il33−/−, but not Il1rl1−/−, mice by immunostaining (Supplemental Figure 9K). We also confirmed the lack of influence on Sftpc+ AT2 cell expansion in these mouse strains using this approach (Supplemental Figure 9, K and L). Correction of basal ESC expansion was associated with attenuation of airway hyperreactivity in Il33−/− compared with WT mice 49 days after infection (Supplemental Figure 9, M and N), a sign of functional benefit that was also not found in Il1rl1−/− mice in a previous study (28). These findings suggest a special role for basal ESC expansion in controlling barrier responsiveness.

**Basal ESC function is required for homeostasis and PVLD.** To fully assign barrier function and/or dysfunction to IL-33–controlled basal ESCs, we undertook a genetic strategy for selective inactivation of this cell population. Thus, we crossed Krt5-Cre-Frt2 mice with newly generated Il33fl/fl mice (Supplemental Figure 10, A and B) to generate Krt5-Cre-Frt2 Il33fl/fl mice for conditional deletion of Il33 in Krt5-expressing basal cells using a tamoxifen treatment scheme with a 3-week drug washout period (Supplemental Figure 10C).
as monitored by flow cytometry was significantly attenuated in tamoxifen-treated Krt5-Cre-Ert2 Il33fl/fl mice (Figure 10D). There was no significant change in the corresponding increases in Aqp3–cells (in a gate that included AT2 cells), thus confirming the treatment’s specificity (Figure 10D). Similarly, basal cell proliferation (based on Ki-67 immunostaining; Figure 10E) and consequent cell numbers (based on Krt5 immunostaining; Figure 10F) were markedly downregulated, without affecting the expression of comparable markers of AT2 cells (Figure 10G) in tamoxifen-treated mice, as confirmed by quantitative morphology (Figure 10H).

Tamoxifen-treated mice also showed a marked downregulation of mRNA markers of basal cells (Figure 11A), with no effect on the expression of the AT2 cell marker IL-33 (Figure 11B), still attenuated expression of markers of type 2 inflammation (Figure 11C) and mucus production (Figure 11D), and the associated lung histopathology (Figure 11, E and F). In addition, the usual Aqp3 +Pdpn+ cell accumulation in bronchiolar-alveolar remodeling regions, but not the associated Sftpc+ AT2 hyperplasia in alveolar sites, was also markedly decreased 49 days after infection (Figure 11, G and H). In line with a correction of the cellular phenotypes of disease, we also found functional improvements marked by corrections in blood oxygen desaturation (Figure 11I) and airway hyperreactivity (Figure 11J) in tamoxifen-treated, basal cell–depleted mice compared with control mice 49 days after SeV infection.

A distinct feature of Krt5-Cre-Ert2 Il33fl/fl mice was the capacity for attenuation of PVLD despite a preserved induction of Il33.
expression (Figure 11B). This combination was distinct from disease blockade in Il33−/− mice, raising the possibility that basal cells might be activated to also influence IL-33–responsive immune cells. Indeed, macrophage accumulation marked by F4/80 immunostaining was significantly attenuated in lung sections from tamoxifen-treated versus untreated Krt5-Cre-Ert2 Il33fl/fl mice (Figure 12, A and B). Moreover, the pattern of macrophage accumulation resembled the localized sites of basal cell expansion and remodeling (based on similar regional changes shown in Figure 10F, Supplemental Figure 9, I and K, and Figure 12A). As a basis for this effect, scRNA-Seq revealed that the macrophage chemokine Cxcl17 was induced primarily in basal cells and the basal cell-
Figure 10. Selective basal ESC depletion in PVLD. (A) Protocol scheme for analysis of Krt5-Cre-Ert2 Il33<sup>fl/fl</sup> mice with or without tamoxifen (Tam) treatment followed by SeV infection. (B) Body weights of mice under the conditions in A. (C) Lung levels of SeV-NP RNA in mice under the conditions in A. (D) Cell numbers determined by flow cytometry of lung epithelial cells based on Aqp3 and EpCAM expression after 21 days under the conditions in A. (E) Immunostaining for Ki-67 plus Aqp3 or Sftp3 in lung sections from Krt5-Cre-Ert2 Il33<sup>fl/fl</sup> mice after 12 days under the conditions in A. Scale bars: 400 μm and 100 μm (enlarged insets). (F) Immunostaining for Krt5, 49 days after SeV infection for the conditions in A. Scale bar: 1 mm. (G) Immunostaining for Sftp3 and IL-33 under the conditions in F. Scale bar: 400 μm. (H) Quantitation of staining for the conditions in E and F. Data represent results from a single experiment with 4–5 mice per condition, and experiments were replicated twice. *P < 0.05, by ANOVA with Bonferroni correction.
derived lineage (Figure 12C). Thus, Cxcl17 mRNA levels were 100-fold higher in the basal cell lineage than in the AT2 cell lineage. In addition, lung levels of Cxcl17 were attenuated (Figure 12D) in the same pattern as for macrophage accumulation (Figure 12B). Further, mRNA induction identified with scRNA-Seq of EpCAM+ epithelial cells was linked to Cxcl17 protein expression localized to Aqp3+ bronchiolar and bronchiolar-alveolar remodeling regions in lung sections 49 days after SeV infection (Figure 12E). Together, the findings establish basal ESC capabilities of homeostatic function at epithelial barrier sites in skin and gut under baseline conditions but, alternatively, of remodeling and inflammatory disease activities at a corresponding barrier site in the lung after respiratory viral infection.

Discussion

To address the role of barrier epithelial cells in host protection versus disease, we performed comprehensive single-cell and transgenic analyses of a mouse model of lung disease that develops after a characteristic centrilobular pattern of infection with a natural respiratory pathogen. We compared the findings with barrier behavior at baseline without infection in lung, skin, or gut sites. The combined approach identified a distinct subset of basal ESCs that maintain skin and gut barriers under normal conditions and instead orchestrates remodeling and inflammatory disease in the lung after severe viral infection. In both cases, basal ESCs cross an IL-33–linked checkpoint for cell growth and survival. In the case of viral infection in the lung, a subset of basal ESCs engaged this mechanism to jump the usual bronchiolar-alveolar junction and grow into contiguous airspaces as a new site for mucinous differentiation and immune activation. The mouse model was critical to defining each of these homeostatic and pathologic components and especially to segregating intracellular versus extracellular IL-33 function in barrier epithelial cell activities as depicted in a summary scheme (Figure 13). Here, we developed 4 key points in this scheme derived from these observations and provide the relevance to barrier maintenance and postviral disease in general, given the overlap with phenotypes across a broad spectrum of lung diseases linked to respiratory viral infections (5, 10–14, 27, 28, 36, 41, 43).

The first of these 4 points relates to the understanding of epithelial cell hyperplasia as a characteristic feature of the response to respiratory viral infection. In mouse models of IAV infection, others recognized that basal epithelial cell hyperplasia could extend to alveolar sites (24) and might reflect a basal progenitor-to-alveolar daughter cell pathway for alveolar repair and functional improvement (25). Related work on the IAV model showed that basal cell expansion might depend on Notch signaling and yield suboptimal alveolar repair (26, 44), whereas another study of IAV found that Wnt-responsive alveolar epithelial progenitor cells within the AT2 cell lineage might be responsible for alveolar regeneration (45). Here, we examined the SeV model to address each of these issues and found that (a) subsets of both basal and AT2 cells were activated for long-term hyperplasia after viral infection; (b) the activated basal cell lineage was not traced into AT2 cells, perhaps consistent with studies of lung development and injury that preserve the bronchiolar-alveolar junction (23, 46); (c) basal cell hyperplasia extended with time to bronchiolar-alveolar sites and was not associated with upregulation of Notch pathway components based on genomics analyses; (d) AT2 cells were absent from bronchiolar-alveolar remodeling sites, whereas AT2 cell hyperplasia developed at separate alveolar remodeling sites; (e) segregated basal and AT2 cell expansion sites fit with a distinct molecular control of these cell populations vis-à-vis growth and survival requirements for IL-33 function; and (f) selective blocking of basal ESC activation via conventional or conditional loss of Il33 gene function improved remodeling (including mucinous differentiation), inflammation (including macrophage infiltration), and function (including hyperreactivity and hypoxia) as readouts of PVLD. Together, these findings reveal the independent nature of basal and AT2 cell hyperplasia and the consequent remodeling and repair endpoints. Whether this paradigm might differ for IAV infection still needs to be defined, but it nonetheless provides mechanistic guidance for generally descriptive single-cell data in humans with lung disease (47) as discussed further below.

The second key point of our work also relates to the question of mechanism, as we identified a basal ESC requirement for the nuclear alarmin IL-33 in cell growth and survival in baseline conditions and after viral infection. This connection was unexpected, given the conventional view of IL-33 as an extracellular cytokine that signals to its ST2 receptor for a type 2 immune response charged for tissue repair (48–51). The alternative possibility of a nuclear signal was proposed in cell culture studies of nuclear IL-33 binding to mitotic chromatin and the regulation of gene transcription via histone modification and transcription factor binding (52–54). Another report discounted this function in endothelial cell cultures (55), but none of these previous studies focused on airway epithelial cells or viral infection, nor did they take advantage of any cell-type differences in IL-33 function. Here, we identified a role for nuclear IL-33 based on several lines of evidence: (a) Il33 but, not Il1r1, gene knockout resulted in the attenuation of basal cell activation of growth and survival genes; (b) the localization of IL-33 to basal cell nuclei corresponded in space and time to basal cell activation; (c) the effect of IL-33 on basal cells was maximal when secreted IL-33 levels were still undetectable; and (d) Il33 gene knockout resulted in loss of the expected chromatin accessibility signal selectively in a cycling population of basal epithelial cells. Together, these findings are most compatible with the idea that IL-33 exerts nuclear control of cell-cycle activation and cell survival via autocrine signaling that is separate from extracellular ST2 activation via paracrine signaling. Additional work is needed to link IL-33 to specific interactions with nuclear proteins and epigenetic modification as a basis for immune training of basal ESCs, as found in innate immune cells. However, our data on chromatin accessibility at the Il33 gene promoter and enhancer regions (including the potential for STAT3-binding sites) provide a roadmap for addressing the regulation of IL33 and IL-33 target genes. Our study showing that nuclear IL-33 function is required for basal but not AT2 cell growth provides an initial molecular basis for distinct responses of these cell populations to lung injury.

The third notable point of our findings relates to the interaction of basal ESCs with immune cell partners. As discussed above, previous work highlighted the role of macrophages...
Figure 11. Basal ESC requirement for gene expression, remodeling, and functional readouts for PVLD. (A–D) Levels of mRNA markers for basal cells (A), AT2 cells (B), type 2 immune response (C), and mucus production (D), 49 days after SeV or SeV-UV infection in Krt5-Cre-ERT2 Il33fl/fl mice with or without tamoxifen treatment. (E) PAS and hematoxylin staining of lung sections for the conditions in A. Scale bar: 1 mm. (F) Quantitation of staining of lung sections in E. (G) Immunostaining for Aqp3 and Pdpn under the conditions in A. Scale bar: 1 mm. (H) Immunostaining for Sftpc and Pdpn under the conditions in A. Scale bar: 200 μm. (I) Oximeter levels for blood oxygen saturation (SpO2) at baseline and after inhaled MCh under the conditions in A. (J) Values for airway resistance (Rrs) at baseline and after inhaled MCh under the conditions in A. Data represent results from a single experiment with 5 mice per condition, and experiments were replicated twice. *P < 0.05, by ANOVA with Bonferroni correction.
IL-33+ basal cells might be key to recruiting macrophages and DC (monocytic DC) contributions to PVLD (8, 35). Our results add that ILC2 and myeloid (tissue macrophage and monocyte-derived cells) infection serve to establish distinct roles for innate lymphoid cells in PVLD appears to hold in varying forms across a broad sample of experimental animal models and humans.

However, an alternative pathway toward remodeling disease was less certain. In that regard, recent studies of SARS-CoV-2 infection have demonstrated SARS-CoV-2 infection (27, 43). Similarly, the recently documented proteomic expression of CTSL1 in COVID-19 lung tissue (61) and TNFRSF12A in basal cell–derived organoids (62) was also identified in our SeV model (in basal cell cluster 2), thus assigning a cell location in vivo and again underlining the stereotyped epithelial cell response to severe respiratory viral infections. The data also fit with the capacity of basal progenitor cell clones to cause inflammation, fibrosis, and mucinous differentiation when transplanted from patients with lung disease into mouse lung (63). Here, we proved this concept in vivo with the identification of a subset of basal ESCs that were modified by viral infection as a requirement for lung remodeling disease in experimental models designed to mimic the features of PVLD in humans. Studies are needed and are currently underway to determine whether similar cell and molecular events might be found after influenza virus and coronavirus infection in animal models and humans.

In summary, we anticipate that our findings will provide a new perspective on epithelial barrier function and a mechanistic basis for marking and correcting PVLD. To place the present findings in perspective, we recognize that mucociliary removal and epithelial wound responses represent some of the most ancient systems for defending against environmental injury. However, there might also be sufficient evolutionary pressure for an innate walling-off response that it can transform to drive remodeling disease under some circumstances. Thus, the present paradigm connects the primordial role of the epithelial barrier to the aberrant disease process found in susceptible hosts based on specific cell and molecular events. As an example, stress kinases such as MAPK13 might regulate both epithelial cell growth and mucinous differentiation and might therefore provide a suitable target for intervention and for defining additional factors that regulate progressive tissue

Figure 12. Basal ESC immune-signaling function in PVLD. (A) Immunostaining for F4/80 on day 49 after SeV or SeV-UV infection of Krt5-Cre-ERT2 Il33fl/fl mice with or without tamoxifen treatment. Scale bar: 1 mm. (B) Quantitation of staining for the images in A. (C) Dot plot for Cxcl17 gene expression from scRNA-Seq analysis of lung epithelial cells for combined sample conditions (12 and 21 days after SeV infection or PBS challenge). (D) Lung levels of Cxcl17 mRNA for the conditions in A. (E) Immunostaining for Cxcl17 and Aqp3 in lung sections after 49 days under the conditions in A. Scale bar: 400 μm. Data represent results from a single experiment with 5 mice per condition, and experiments were replicated twice. *P < 0.05, by ANOVA with Bonferroni correction.
remodeling (64). The markers for the relevant basal ESC subset identified in our study thus provide a roadmap for a precise, disease-modifying strategy relevant to the pressing and widespread consequences of severe respiratory viral infections.

**Methods**

Details on mouse line generation and treatment, RNA-Seq analysis, real-time qPCR assay, immunohistochemistry and immunocytochemistry, flow cytometry and FACS, epithelial cell culturing, scRNA-Seq analysis, scATAC-Seq analysis, and lung function testing are provided in the Supplemental Methods.

**Data availability.** The RNA-Seq and scRNA-Seq data were deposited in the NCBI’s Gene Expression Omnibus (GEO) database (GEO GSE180392, RNA-Seq; GSE178517, scRNA-Seq; GSE178711, scATAC-Seq).

**Study approval.** All mouse husbandry and experimental procedures were approved by the Animal Studies Committees of the Washington University School of Medicine, in accordance with NIH guidelines.

**Statistics.** All data presented are expressed as the mean ± SEM. For these data, statistical differences between means for sample conditions were assessed using 1-way ANOVA with Bonferroni correction for multiple comparisons. For violin plot formats of single-cell gene expression data, statistical differences between the means for sample conditions were assessed using a Mann-Whitney U test with Bonferroni correction for multiple comparisons. For all data, the significance threshold was set at a P value of less than 0.05. The number of mice for each condition and the number of replicate experiments are indicated in the figure legends.

**Acknowledgments**

We thank the Pulmonary Morphology Core, the Anatomic and Molecular Pathology Core, Siteman Flow Cytometry Core, Pathology-Immunology Transgenic-Microinjection Core, the Genome Technology Access Core, the Genome Engineering and iPSC Center, and Di Wu and Xiaohua Jin for their technical support. This work was supported by grants from the National Heart, Lung, and Blood Institute (NHLBI), NIH (R35-HL145242); the National Institute of Allergy and Infectious Diseases (NIAID), NIH (R01-AI130591); the Department of Defense (PR190726); the Cystic Fibrosis Foundation; the Beber Meyer Fund; the Hardy Trust; and the Schaefer Fund.

**Address correspondence to:** Michael J. Holtzman, Washington University School of Medicine, Campus Box 8052, 660 South Euclid Avenue, Saint Louis, Missouri 63110, USA. Phone: 314.362.8970; Email: mjholtzman@wustl.edu.


